Tuesday, October 5, 2010

Aurobindo Pharma; Geared to enter a billion dollar club; BUY; Target Price Rs1,242

Aurobindo Pharma

Reco: BUY

CMP: Rs1,066

Target Price: Rs1,242

Geared to enter a billion dollar club

·      Hyderabad SEZ facility becomes operational, capacity to ramp-up substantially by FY11E

·      Higher capacity utilization and entry into niche segments will lead to margin improvement

·      Tie up for ECB loan of US$125mn will considerably reduce the leverage risk on FCCBs

·      Deal with Astrazeneca covers 25 oral solid and sterile products across 40 countries, supplies to commence by end of FY12E     

·      The company has envisioned a mission to be US$2bn company by FY14E, implying FY10-14E revenue CAGR of ~26%

--
Safe Harbor:
The information contained and provided on this Website provides Investment advice for the education of investors. The posts are an information service only. Recommendations, opinions or suggestions are given with the understanding that readers acting on this information assume all risks involved. We do not assume any responsibility or liability resulting from the use of such information, judgment and opinions for Trading or Investment purposes.
 
You received this message because you are subscribed to the Google Groups "Investors Please Listen !" group.
To post to this group, send email to investorspleaselisten@googlegroups.com
To unsubscribe from this group, send email to
investorspleaselisten+unsubscribe@googlegroups.com For more options, visit this group at http://groups.google.com/group/investorspleaselisten?hl=en

No comments:

Blog Archive

Life Insurance | Health Insurance | Auto Insurance


Investors Please Listen !

 
More than 100 kinds of Insurance products from more than
20 companies under one roof.



Call: 9818269396 
investorspleaselisten@in.com
www.investorspleaselisten.blogspot.com

 

 

Safe Harbor:

The information contained and provided on this Website provides Investment advice for the education of investors. The posts are an information service only. Recommendations, opinions or suggestions are given with the understanding that readers acting on this information assume all risks involved. We do not assume any responsibility or liability resulting from the use of such information, judgment and opinions for Trading or Investment purposes.
Powered by Olark
Advertising Learn to Invest